Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $141.7K
- Enterprise value
- $141.7K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.01
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 33.0M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
First Choice Healthcare Solutions is abandoning its money-losing orthopedic and physical therapy practice to build a national chain of wellness clinics offering anti-aging, weight loss, hormone therapy, and compounded pharmacy services. Revenue will come from a mix of insurance-reimbursed primary care delivered mainly by nurse practitioners and cash-pay quality-of-life treatments sold through the acquired Good Clinic and Livewell brands. The company is mid-pivot after exiting bankruptcy in 2022, posted a $7 million net loss in 2025 against a $74.7 million accumulated deficit, and operates with a one-person board.
Generated from FCHS's filing dated 2026-03-11
Key risks
- Going concern: $7.06M net loss in 2025 and $74.7M accumulated deficit while pivoting strategy away from legacy orthopedic business.
- Execution risk: Unproven pivot to wellness clinics requires integrating $17.3M Pointe Medical and $3.5M Good Clinic acquisitions post-bankruptcy.
- Governance red flags: Sole board member is CEO; former CEO pled guilty to securities fraud conspiracy, forcing 2020 bankruptcy.
Generated from FCHS's filing dated 2026-03-11
Profitability
Return on equity
17.6%
30.6%Return on assets
-172.0%
101.6%Leverage
Debt / equity
-1.10×
4.8%Debt / assets
1076.6%
47.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-1.4M | -2.7% | — |
Q4 2025 2025-12-31 | — | — | $-3.5M | -9515.2% | — |
Q3 2025 2025-09-30 | — | — | $-1.5M | -79.0% | — |
Q2 2025 2025-06-30 | — | — | $-639.4K | +65.7% | — |
Q1 2025 2025-03-31 | — | — | $-1.4M | -16.0% | — |
Q4 2024 2024-12-31 | — | — | $36.8K | — | — |
Q3 2024 2024-09-30 | — | — | $-817.2K | +73.0% | — |
Q2 2024 2024-06-30 | — | — | $-1.9M | +29.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on FCHS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for FCHS in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns FCHS
No institutional holdings on file for FCHS yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
- 1
With $7.1M net loss in 2025 versus $3.9M in 2024 and a $74.7M accumulated deficit, what is your specific runway and next financing trigger?
- 2
Cash burn from operations dropped to $549K while net loss nearly doubled—what non-cash charges drove that gap and are they recurring?
- 3
The $17.3M Pointe Medical/Livewell acquisition was signed July 2023—has it closed, and if not, what are the financing contingencies?
Refreshed when FCHS files a new report · last from 2026-03-11